{"created":"2023-05-15T14:52:27.820026+00:00","id":71630,"links":{},"metadata":{"_buckets":{"deposit":"4ed0b893-6670-4c00-8afa-a7734b4ec9ce"},"_deposit":{"created_by":1,"id":"71630","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"71630"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00071630","sets":["10:28"]},"author_link":["704752","704749","704750","704741","704738","704730","704739","704754","704748","704753","704742","704746","704734","704728","704733","704751","704731","704736","704735","704732","704745","704729","704740","704747","704744","704743","704737"],"item_10005_date_7":{"attribute_name":"発表年月日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2014-06-09","subitem_date_issued_type":"Issued"}]},"item_10005_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Objective: To investigate characteristics of [11C]PBB3 binding and\nits relation with clinical aspects in patients with progressive\nsupranuclear palsy (PSP) and corticobasal syndrome (CBS).\nBackground: [11C]PBB3 is a novel tau imaging positron emission\ntomography (PET) ligand, which could visualize the tau deposition in\nAlzheimer’s disease (AD) and non-AD tauopathies such as PSP,\nCBS and frontotemporal dementia.\nMethods: Participants included 10 PSP patients, 9 patients with\ncorticobasal syndrome (CBS), 19 AD patients, and 20 age and\ngender matched healthy controls (HCs). A dose (about 10 mCi) of\n[11C]PBB3 was intravenously injected and sequential PET scans\nwere performed for 70 min. We also performed PET scan with a\nplaque-binding agent, [11C]PIB (about 10 mCi), for 70 min and threedimensional\nT1-weighted MRI. Standardized uptake value ratio\n(SUVR) was calculated for each PET image using the cerebellar\ncortex as reference region. Amyloid deposition was verified by visual\nassessment of SUVR images of [11C]PIB PET. As for [11C]PBB3\nPET data, group analysis among each group was performed by oneway\nANOVA using statistical parametric mapping software (spm5).\nResults: One CBS patient and 17 of 19 AD patients were PIBpositive,\nand all the rest participants were PIB-negative. One PIBpositive\nCBS and two PIB-negative AD patients were excluded from\ngroup analysis. [11C]PBB3 was accumulated in lesions associated\nwith neurological symptoms in PSP, CBS and AD patients. To be\nspecific, [11C]PBB3 binding was significantly increased in the\nbrainstem, basal ganglia, thalamus and dentate nucleus in PSP\npatients compared to HCs. In PIB-negative CBS patients,\nremarkable uptake of [11C]PBB3 was observed in basal ganglia and\nthe neocortex including the supplementary motor area (SMA) and\nthe peri-Rolandic area compared to HCs. Furthermore, [11C]PBB3\nretention observed in PIB-positive CBS patient extended the\nneocortex as well as the entire limbic system, resembling AD\npatients with profound cognitive decline. Some brain lesions with\n[11C]PBB3 binding exhibited brain atrophy in PSP, CBS and AD\npatients.\nConclusions: The present study demonstrated that distribution\npatterns of [11C]PBB3 binding reflect the differences in tau\ndistribution in PSP, CBS and AD patients, which are highly\ncompatible with neurological manifestation in each disorder.","subitem_description_type":"Abstract"}]},"item_10005_description_6":{"attribute_name":"会議概要（会議名, 開催地, 会期, 主催者等）","attribute_value_mlt":[{"subitem_description":"第18回国際パーキンソン病・運動障害疾患会議（MDS2014）","subitem_description_type":"Other"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Shimada, Hitoshi"}],"nameIdentifiers":[{"nameIdentifier":"704728","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Hirano, Shigeki"}],"nameIdentifiers":[{"nameIdentifier":"704729","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Shinotoh, Hitoshi"}],"nameIdentifiers":[{"nameIdentifier":"704730","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Furukawa, Shogo"}],"nameIdentifiers":[{"nameIdentifier":"704731","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Eguchi, Yoko"}],"nameIdentifiers":[{"nameIdentifier":"704732","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Takahata, Keisuke"}],"nameIdentifiers":[{"nameIdentifier":"704733","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kimura, Yasuyuki"}],"nameIdentifiers":[{"nameIdentifier":"704734","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ikoma, Youko"}],"nameIdentifiers":[{"nameIdentifier":"704735","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yamada, Makiko"}],"nameIdentifiers":[{"nameIdentifier":"704736","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Zhang, Ming-Rong"}],"nameIdentifiers":[{"nameIdentifier":"704737","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ito, Hiroshi"}],"nameIdentifiers":[{"nameIdentifier":"704738","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Higuchi, Makoto"}],"nameIdentifiers":[{"nameIdentifier":"704739","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kuwabara, Satoshi"}],"nameIdentifiers":[{"nameIdentifier":"704740","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Suhara, Tetsuya"}],"nameIdentifiers":[{"nameIdentifier":"704741","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"島田 斉","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"704742","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"平野 成樹","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"704743","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"篠遠 仁","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"704744","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"古川 彰吾","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"704745","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"江口 洋子","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"704746","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"高畑 圭輔","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"704747","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"木村 泰之","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"704748","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"生駒 洋子","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"704749","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"山田 真希子","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"704750","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"張 明栄","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"704751","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"伊藤 浩","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"704752","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"樋口 真人","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"704753","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"須原 哲也","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"704754","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"conference object","resourceuri":"http://purl.org/coar/resource_type/c_c94f"}]},"item_title":"In vivo tau PET imaging using [11C]PBB3 in patients with PSP and CBS","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"In vivo tau PET imaging using [11C]PBB3 in patients with PSP and CBS"}]},"item_type_id":"10005","owner":"1","path":["28"],"pubdate":{"attribute_name":"公開日","attribute_value":"2015-04-20"},"publish_date":"2015-04-20","publish_status":"0","recid":"71630","relation_version_is_last":true,"title":["In vivo tau PET imaging using [11C]PBB3 in patients with PSP and CBS"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T19:49:07.723881+00:00"}